Liraglutide and semaglutide, glucagon-like peptide 1 (GLP-1) agonists, are the latest drugs approved for the treatment of obesity, and both have been shown to induce significant body weight loss. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.